Domov › Velika depresivna motnja › Alabama
Klinične študije za Velika depresivna motnja v Alabama
15 študij za Velika depresivna motnja išče udeležence na lokacijah v Alabama.
Mesta v Alabama
Uradno besedilo študije (angleško)
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- University of Alabama at Birmingham - School of Medicine, Birmingham
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07775300Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- University of Alabama at Birmingham, Huntsville
Vključevanje udeležencevFaza 3
Starost 18–65 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05850689A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- University of Alabama at Birmingham, Birmingham
Vključevanje udeležencevFaza 3
Starost 12–17 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07227454A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- UAB Psychiatry and Behavioral Neurology, Birmingham
Vključevanje udeležencevFaza 3
Starost 18–85 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06793397A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- University of Alabama at Birmingham, Huntsville Regional Medical Campus, Huntsville
Vključevanje udeležencevFaza 3
Starost 18–74 · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT07076407Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- University of Alabama at Birmingham - Dept. of Psychiatry, Birmingham
Vključevanje udeležencev
Starost 22–70 · Vsi spoli · Posodobljeno 28. avg. 2026 · NCT06423430Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
- Birmingham VA Medical Center, Birmingham, AL, Birmingham
- Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 14. avg. 2026 · NCT07226232NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Huntsville
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 11. avg. 2026 · NCT06911112Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- University of Alabama at Birmingham, Birmingham
Vključevanje udeležencevFaza 2
Starost 18–64 · Vsi spoli · Posodobljeno 3. avg. 2026 · NCT06547489Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Huntsville
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 24. jul. 2026 · NCT06966401Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
- University of Alabama at Birmingham, Birmingham
- UAB Huntsville Regional Medical Campus, Huntsville
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 10–24 · Vsi spoli · Posodobljeno 13. jul. 2026 · NCT05437588A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Harmonex /ID# 277517, Dothan
Vključevanje udeležencevFaza 2
Starost 18–65 · Vsi spoli · Posodobljeno 15. jun. 2026 · NCT07276997MicroRNA Correlates of Childhood Maltreatment and Suicidality
- University of Alabama at Birmingham, Birmingham
- UAB Huntsville Regional Medical Campus, Huntsville
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 18–60 · Vsi spoli · Posodobljeno 30. mar. 2026 · NCT04923685Using TMS to Understand Neural Processes of Social Motivation
- Auburn University, Auburn
Vključevanje udeležencev
Starost 25–50 · Vsi spoli · Posodobljeno 3. mar. 2026 · NCT06274112Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #131, Birmingham
Vključevanje udeležencevFaza 2
Starost 18–65 · Vsi spoli · Posodobljeno 20. jan. 2026 · NCT06633016Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.